Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) open the trading on Wednesday, with a bit cautious approach as it glided -1.82% to $31.87, before settling in for the price of $32.46 at the close. Taking a more long-term approach, RARE posted a 52-week range of $25.81-$53.47.
It was noted that the giant of the Healthcare sector posted annual sales growth of 2.45% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 2.45%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 12.00%. This publicly-traded company’s shares outstanding now amounts to $96.37 million, simultaneously with a float of $89.55 million. The organization now has a market capitalization sitting at $3.07 billion. At the time of writing, stock’s 50-day Moving Average stood at $31.44, while the 200-day Moving Average is $35.00.
Ultragenyx Pharmaceutical Inc (RARE) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Ultragenyx Pharmaceutical Inc’s current insider ownership accounts for 7.07%, in contrast to 95.18% institutional ownership. According to the most recent insider trade that took place on Oct 13 ’25, this organization’s Chief Financial Officer sold 7,942 shares at the rate of 31.51, making the entire transaction reach 250,252 in total value, affecting insider ownership by 98,227. Preceding that transaction, on Sep 18 ’25, Company’s SVP, Chief Accounting Officer sold 64 for 29.17, making the whole transaction’s value amount to 1,867. This particular insider is now the holder of 50,242 in total.
Ultragenyx Pharmaceutical Inc (RARE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.33 per share during the current fiscal year.
Ultragenyx Pharmaceutical Inc’s EPS increase for this current 12-month fiscal period is 12.00% and is forecasted to reach -4.20 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 39.16% through the next 5 years, which can be compared against the 2.45% growth it accomplished over the previous five years trading on the market.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Let’s observe the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). It’s Quick Ratio in the last reported quarter now stands at 2.30. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.87.
In the same vein, RARE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.94, a figure that is expected to reach -1.19 in the next quarter, and analysts are predicting that it will be -4.20 at the market close of one year from today.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
[Ultragenyx Pharmaceutical Inc, RARE] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 21.27% While, its Average True Range was 38.82.
Raw Stochastic average of Ultragenyx Pharmaceutical Inc (RARE) in the period of the previous 100 days is set at 36.59%, which indicates a major fall in contrast to 44.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.54 that was higher than 1.28 volatility it exhibited in the past 100-days period.
